H3B 8800

Drug Profile

H3B 8800

Alternative Names: H3B-8800

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator H3 Biomedicine
  • Developer Eisai Inc; H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action SF3B1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 14 Aug 2017 H3B 8800 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 14 Aug 2017 H3B 8800 receives Orphan Drug status for Chronic myelomonocytic leukaemia in USA
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia and Chronic myelomonocytic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top